RECURSION PHARMACEUTICALS, INC. 8-K

What Happened

• Recursion Pharmaceuticals, Inc. (RXRX) filed an 8-K reporting that Christopher Gibson, Ph.D., Chair of the Board and a member of the Research & Development, Technology, and Corporate Social Responsibility Committees, informed the company on April 28, 2026 that he will not stand for re-election as a Class II director at the 2026 Annual Meeting.
• The company issued a press release on April 30, 2026 announcing the Board transition. The filing states Dr. Gibson’s decision was not due to any disagreement with the company’s operations, policies, or practices. He will remain Chair and on his committees until his current term expires at the 2026 Annual Meeting.

Key Details

• Notice date: April 28, 2026 (filing and press release dated April 30, 2026).
• Director affected: Christopher Gibson, Ph.D., Chair of the Board; Class II Director.
• Committee memberships: Research & Development, Technology, Corporate Social Responsibility.
• Company disclosure: Decision not due to any disagreement with the company.

Why It Matters

• Leadership continuity: Investors should note the Chair announced he will step down from the board at the 2026 Annual Meeting but will continue in his role until that time, allowing time for an orderly transition or board nominee process.
• Governance signal: The filing explicitly states the departure is not due to disagreement with company policies or operations, which can reduce concern about internal conflict. A change in board composition can still affect oversight and strategic direction, so monitor subsequent filings for any announcement of a new director or Chair succession.